Evidence map›Paper›PMID 40042091›Full record

ArticleJournal of cellular and molecular medicine2025

SERS-Based Assessment of DNA Methylation for the Evaluation of Measurable Residual Disease in Acute Promyelocytic Leukaemia.

Anamaria Bancos, Stefania D Iancu, Vlad Moisoiu, Alexandra Ghiaur, Adrian Bogdan Tigu, Cristina Buran, Georgiana Ion, Camelia Stancioaica, Bogdan Ionescu, Mihaela Dragomir and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Anamaria BancosDepartment of Hematology-Medfuture Research Center for Advances Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
Stefania D IancuFaculty of Physics, Babeș-Bolyai University, Cluj-Napoca, Romania.
Vlad MoisoiuDepartment of Hematology-Medfuture Research Center for Advances Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
Alexandra GhiaurDepartment of Leukemia, Fundeni Clinical Institute, Bucharest, Romania.
Adrian Bogdan TiguMedfuture Research Center for Advances Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Bucharest, Romania.
Cristina BuranDepartment of Hematology-Medfuture Research Center for Advances Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
Georgiana IonFaculty of Physics, Babeș-Bolyai University, Cluj-Napoca, Romania.
Camelia StancioaicaDepartment of Leukemia, Fundeni Clinical Institute, Bucharest, Romania.
Bogdan IonescuDepartment of Leukemia, Fundeni Clinical Institute, Bucharest, Romania.
Mihaela DragomirDepartment of Leukemia, Fundeni Clinical Institute, Bucharest, Romania.
Codruta F BuldusFaculty of Physical Education and Sport, Babeș-Bolyai University, Cluj-Napoca, Romania.
Diana CenariuDepartment of Hematology-Medfuture Research Center for Advances Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
Madalina NistorDepartment of Hematology-Medfuture Research Center for Advances Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
David KegyesDepartment of Hematology-Medfuture Research Center for Advances Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
Diana GuleiDepartment of Hematology-Medfuture Research Center for Advances Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
Nicolae LeopoldFaculty of Physics, Babeș-Bolyai University, Cluj-Napoca, Romania.
Daniel CoriuDepartment of Leukemia, Fundeni Clinical Institute, Bucharest, Romania.ORCID 0000-0002-7251-6079
Ciprian TomuleasaDepartment of Hematology-Medfuture Research Center for Advances Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.ORCID 0000-0002-5770-7811

Funding

Babeș-Bolyai UniversityEuropean Hematology Association PN-IV-P8-8.3-ROMD-2023-0036Iuliu Hatieganu UniversityIuliu Hatieganu University of Medicine and Pharmacy PCD 2022-2024Romanian Academy of ScientistsRomanian GovernmentRomanian Ministry of Research and Innovation PN-III-P4-ID-PCE-2020-1292Romanian Research Ministry PNRR 2024-026
6 · The paper itself

Abstract

Acute promyelocytic leukaemia (APL) is a type of acute myeloid leukaemia characterised by the reciprocal translocation t(15;17), which offers a unique possibility for measurable residual disease (MRD) monitoring by PCR amplification of the PML-RARA transcripts. Surface-enhanced Raman scattering (SERS) is a laser molecular spectroscopy technique that allows the rapid analysis of changes in the DNA methylation pattern associated with malignant transformation. In this study involving 49 DNA samples from bone marrow aspirations from patients with APL, we showed that the DNA from MRD-positive samples exhibited lower SERS intensities of the band at 730 cm

Indexed as

DNA MethylationLeukemia, Promyelocytic, AcuteNeoplasm, ResidualSpectrum Analysis, RamanAdolescentAdultAgedFemalefms-Like Tyrosine Kinase 3HumansMaleMiddle AgedPrincipal Component AnalysisROC CurveYoung Adultfms-Like Tyrosine Kinase 3acute promyelocytic leukaemiaminimal residual diseaseSERS

Identifiers

PMID40042091
PMCPMC11880916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.